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Abstract: An individual’s immune system is driven by both genetic and environmental factors 
that vary over time. To better understand the temporal and inter-individual variability of gene 
expression within distinct immune cell types, we developed a platform that leverages multiplexed 10 
single-cell sequencing and out-of-clinic capillary blood extraction to enable simplified, cost-
effective profiling of the human immune system across people and time at single-cell resolution. 
Using the platform, we detect widespread differences in cell type-specific gene expression between 
subjects that are stable over multiple days. 
 15 
Summary: Increasing evidence implicates the immune system in an overwhelming number of 
diseases, and distinct cell types play specific roles in their pathogenesis.1,2 Studies of peripheral 
blood have uncovered a wealth of associations between gene expression, environmental factors, 
disease risk, and therapeutic efficacy.4 For example, in rheumatoid arthritis, multiple mechanistic 
paths have been found that lead to disease, and gene expression of specific immune cell types can 20 
be used as a predictor of therapeutic non-response.12 Furthermore, vaccines, drugs, and 
chemotherapy have been shown to yield different efficacy based on time of administration, and 
such findings have been linked to the time-dependence of gene expression in downstream 
pathways.21,22,23 However, human immune studies of gene expression between individuals and 
across time remain limited to a few cell types or time points per subject, constraining our 25 
understanding of how networks of heterogeneous cells making up each individual’s immune 
system respond to adverse events and change over time. 
 
Introduction: The advent of single-cell RNA sequencing (scRNA-seq) has enabled the 
interrogation of heterogeneous cell populations in blood without cell type isolation and has already 30 
been employed in the study of myriad immune-related diseases.14,15,18 Recent studies employing 
scRNA-seq to study the role of immune cell subpopulations between healthy and ill patients, such 
as those for Crohn’s disease 41, Tuberculosis 40, and COVID-19 39, have identified cell type-
specific disease relevant signatures in peripheral blood immune cells; however, these types of 
studies have been limited to large volume venous blood draws which can tax already ill patients, 35 
reduce the scope of studies to populations amenable to blood draws, and often require larger 
research teams to handle the patient logistics and sample processing costs and labor. In particular, 
getting repeated venous blood draws within a single day and/or multiple days at the subject's home 
has been a challenge for older people with frail skin and those on low dosage Acetylsalicylic acid.44 
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This dependence on venous blood dramatically impacts our ability to understand the high temporal 40 
dynamics of health and disease. 
 
Capillary blood sampling is being increasingly used in point-of-care testing and has been advised 
for obese, elderly, and other patients with fragile or inaccessible veins.20,42,43,15 The reduction of 
patient burden via capillary blood sampling could enable researchers to perform studies on 45 
otherwise difficult or inaccessible populations, and at greater temporal resolution. To date, scRNA-
seq of human capillary blood has not yet been validated nor applied to study the immune system. 
In order to make small volumes of capillary blood (100 ul) amenable to scRNA-seq we have 
developed a platform which consists of a painless vacuum-based blood collection device, sample 
de-multiplexing leveraging commercial genotype data, and an analysis pipeline used to identify 50 
time-of-day and subject specific genes. The potential of our platform is rooted in enabling large 
scale studies of immune state variation in health and disease across people. The high-dimensional 
temporal transcriptome data could be paired with computational approaches to predict and 
Fig.1 | Experimental workflow and consistency of capillary blood sampling (a) Experimental workflow for 
capillary blood immune profiling 1. Blood is collected using the TAP device from the deltoid. 2. Capillary 
peripheral blood mononuclear cells (CPBMCs) are separated via centrifugation. 3. Red blood cells are lysed and 
removed, and samples from different subjects are pooled together. 4. Cell transcriptomes are sequenced using 
single-cell sequencing. (b) Time-course study design. CPBMCs are collected and profiled from 4 subjects (2 male, 
2 female) each morning (AM) and afternoon (PM) for 3 consecutive days. (c) 2-dimensional t-SNE projection of 
the transcriptomes of all cells in all samples. Cells appear to cluster by major cell type, and then further by subject. 
(d) Immune cell type percentages across all samples shows stable cell type abundances (includes cells without 
subject labels). (e) CD8+ T cells have significantly lower abundance in PM samples vs AM samples, consistent with 
previous findings from venous blood (student t-test performed on AM, PM samples of each subject and then 
combined using Stouffer’s method). Marker colors correspond to subject identity from (c). 
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understand emergence of pathological immune states. Most importantly, our platform makes 
collection and profiling of human immune cells less invasive, less expensive and as such more 55 
scalable than traditional methods rooted in large venous blood draws. 
 
Results: 
Platform for low-cost interrogation of single-cell immune gene expression profiles: Our 
platform is comprised of a protocol for isolating capillary peripheral blood mononuclear cells 60 
(CPBMCs) using a push-button collection device (TAP)15, pooling samples to reduce per-sample 
cost using genome-based demultiplexing16, and a computational package that leverages repeated 
sampling to identify genes that are differentially expressed in individuals or between time points, 
within subpopulations of cells (Fig. 1a). Using a painless vacuum-based blood collection device 
such as the commercial FDA-approved TAP to collect capillary blood makes it convenient to 65 
perform at-home self-collected sampling and removes the need for a trained phlebotomist, 
increasing the ease of acquiring more samples. The isolation of CPBMCs is done using gradient 
centrifugation and red blood cells are further removed via a red blood cell lysis buffer. The cells 
from the different subjects are pooled, sequenced via scRNA-seq using a single reagent kit, and 
de-multiplexed 16 via each subject’s single-nucleotide polymorphisms (SNPs), reducing the per-70 
sample processing cost. Finally, we made our pipeline compatible with genotyping data obtained 
from a commercial service (23AndMe), removing the need for a separate genotyping assay for 
subjects that already have access to their own SNP data. 
 
Single-cell RNA sequencing (scRNA-seq) of low volume capillary blood recovers distinct 75 
immune cell populations stably across time: As a proof-of-concept, we leveraged our scRNA-
seq of capillary blood platform to identify genes that exhibit diurnal behavior in subpopulations of 
cells and find subject-specific immune relevant gene signatures. We performed a three-day study 
in which we processed capillary blood from four subjects in the morning and afternoon, totaling 
25,255 cells across 22 samples (Fig. 1b). Major immune cell types such as T cells (CD4+, CD8+), 80 
Natural Killer cells, Monocytes (CD14+, CD16+), and B cells are present in all subjects and time 
points with stable expression of key marker genes (Fig. 1d, Fig. S1), demonstrating that these 
signals are robust to technical and biological variability of CPBMC sampling. Furthermore, cells 
within subjects cluster closer together than cells between subjects, suggesting that subjects have 
unique transcriptomic fingerprints (Fig. 1c). Additionally, we observed significantly higher 85 
(p=2.8x10-2, one-sided student t-test) CD8+ T cell abundance in the morning across all subjects 
(Fig. 1e), corroborating previous findings from venous PBMCs about the daytime dependence of 
the adaptive immune system composition.7 
 
High frequency scRNA-seq unveils new diurnal cell type-specific genes: Genes driven by time-90 
of-day expression, such as those involved in leukocyte recruitment27 and regulation of oxidative 
stress28, have been determined to play an important role in both innate and adaptive immune cells8. 
Medical conditions such as atherosclerosis, parasite infection, sepsis, and allergies display distinct 
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time-of-day immune responses in leukocytes29, suggesting the presence of diurnally expressing 
genes that could be candidates for optimizing therapeutic efficacy via time-of-day dependent 95 
administration. However, studies examining diurnal gene expression in human blood have been 
limited to whole blood gene panels via qPCR, or bulk RNA-seq.9,37, 38 
 
Leveraging our platform, which enables single-cell studies of temporal human immune gene 
expression, we detected 366 genes (FDR < 0.05, multiple comparison corrected) exhibiting diurnal 100 
activity within at least one cell subpopulation (Fig. 2a). Among the 20 top diurnally classified 
genes, we found that 50% of those genes were previously correlated with circadian behavior (Table 
S1), such as DDIT49 (Fig. 2b), SMAP226, and PDIA336. However, only 101/366 (27.6%) of these 
genes are detected as diurnal at the whole population level (FDR < 0.05, multiple comparison 
corrected), suggesting there may be many more diurnally-varying genes than previously 105 
discovered. For example, IFI16 and ARID1A (Fig. 2c) have diurnal expression only in NK cells 
and B cells, respectively, and display previously unreported transcriptional diurnal patterns. In 
particular, ARID1A is a regulator of higher order chromatin structure and mutations of this gene 
have been implicated in B-cell lymphomas.18 Given previous evidence of increased efficacy of 
time-dependent chemotherapy administration23,24 and tumor cells exhibiting out-of-sync behavior 110 
Fig. 2 | Diurnal variability in subpopulations of capillary blood (a) Magnitude (Z-score) of the difference in AM 
vs PM gene expression across the whole population of cells (x) vs the cell type with the largest magnitude Z-score 
(y). Points above or below the significance lines (FDR < 0.05, multiple comparison correction) display different 
degrees of diurnality. The size of each marker indicates the abundance of the gene (the largest percent of cells in a 
subpopulation that express this gene). (b) Distribution of expression of DDIT4, a previously identified circadian 
rhythm gene9, shows diurnal signal across all cells, as well as individual cell types, such as natural killer (NK) cells. 
u indicates the mean fraction of transcripts per cell (gene abundance). (c) Example of newly identified diurnal genes, 
ARID1A and IFI16 that could be missed if analyzed at the population level (d) Example of a gene, EAF2, that could 
be falsely classified as diurnal (i) without considering cell type subpopulations due to a diurnal B cell abundance 
shift (ii). 
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compared to normal cells25, understanding ARID1A’s diurnal expression pattern can potentially 
guide timely administration of candidate therapeutics. Out of the identified 366 diurnally-varying 
genes, 162 (44%) are considered druggable under the drug gene interaction database 
(http://www.dgidb.org/). 
 115 
scRNA-seq profiling distinguishes diurnal gene expression from cell type abundance 
changes: We also detected 250 genes (FDR < 0.05, multiple comparison corrected) exhibiting 
diurnal behavior when analyzed at the population level, such as EAF2, that do not display diurnal 
variation in any of our major cell types (Fig. 2d.i). Such false positives may come from diurnal 
shifts in cell type abundance rather than up- or down-regulation of genes. In the case of EAF2, 120 
which is most abundant in B cells, we hypothesized that the diurnality detected at the population 
level was a result of an increase of B cell abundance in the afternoon, and verified this in our data 
(p=5.0x10-3, one-sided student-t test) (Fig. 2d.ii). This finding highlights the importance of looking 
at expression within multiple cell types to avoid potentially misleading mechanistic hypotheses. 
 125 
Individuals exhibit robust cell type-specific differences in genes and pathways relevant to 
immune function: Gene expression studies of isolated cell subpopulations across large cohorts of 
people have revealed a high degree of variability between individuals that cannot be accounted for 
by genetics alone, with environmental effects that vary over time likely playing a critical role.33, 35 
Furthermore, these transcriptomic differences have been linked to a wide range of therapeutic 130 
responses, such as drug-induced cardiotoxicity.34 However, while immune system composition 
and expression has been shown to be stable over long time periods within an individual, acute 
immune responses generate dramatic immune system changes, meaning that large single time point 
population studies are unable to establish whether variability between individuals is stable or the 
result of dynamic response to stimuli.32 135 
 
To probe the stability of individual gene expression signatures at the single-cell level, we used our 
pipeline to identify genes whose variation in gene expression is most likely caused by intrinsic 
intersubject differences rather than high frequency immune system variability. We compared the 
mean gene expressions of all time points between subjects in all cell types and identified 1251 140 
genes (FDR < 0.05, multiple comparison corrected) that are differentially expressed in at least one 
subpopulation of cells. Like Whitney, et al., we found MHC class II genes, such as HLA-DRB1, 
HLA-DQA2, and HLA-C (Fig. 3a) to be among the largest sources of variation between subjects.5 
Additionally, we found that DDX17, which was classified by Whitney et al. as a gene with high 
intersubject variability, but low intrasubject variability via repeat sampling over longer time scales, 145 
may be a new class of temporally varying gene that varies by day of week, having consistently 
increasing expression each subsequent sampling day. This stresses the importance of high 
frequency sampling for identifying genes with the most intrinsic interindividual variability. 
 
 150 
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Numerous subject-specific genes are revealed in specific immune cell types: Within the 1251 
genes with intrinsic interindividual variability, we found myriad disease-relevant genes for all 
subjects and cell types, which can be explored at our interactive online portal (http://capblood- 
seq.caltech.edu). As just one example, subject S1’s monocytes have a consistent downregulation 
(p=2.0x10-6, two-sided student t-test) of LIPA, a gene that is implicated in Lysosomal Acid Lipase 155 
Fig.3 | Subject variability in immune and disease-relevant genes and pathways (a) Magnitude (log2 F statistic) of 
the variability in expression of genes between different cell types (x) and between subjects (y). 1251/7034 (17.8%) of 
genes are above the subject specificity significance line (FDR < 0.05, multiple comparison correction) and are 
classified as subject-specific. Several MHC class II genes (HLA-X) are strongly subject-specific, consistent with 
previous findings5. (b) KEGG pathways grouped into categories and their enrichment (Z-score from 2-proportion Z-
test) among the top 250 diurnally and subject-varying genes vs all genes. Immune system and disease pathways are 
significantly enriched (p=0.059), supportive of the conclusion that immune and disease-related genes are highly 
subject dependent. The large circles indicate the enrichment of the category overall, and the sizes of the smaller 
pathway points indicate the number of genes associated with the pathway. (c) Subject and cell type specific gene 
examples for each subject and cell type with the upper row displaying the trace of mean gene expression across time-
points and the bottom row showing gene abundance shifts for the subjects of interest. 
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Deficiency (Fig. 3c). Given the low abundance of monocytes in blood samples, such findings 
would typically only be discovered from a targeted blood test or RNA sequencing of isolated 
monocytes, either of which would only be performed if the disease was already suspected; this 
showcases how automated discovery in heterogeneous cell populations can be leveraged for 
personalized, preventative care. 160 
 
Immune function and disease pathways are enriched in subject-specific genes: Given that 
genes do not act alone, we also found cell type-specific pathway differences among subjects. In 
particular, Subject 2’s S100A8, S100A9, and S100A12 genes, calcium-binding proteins that play 
an important role in macrophage inflammation, are significantly downregulated in monocytes 165 
(pS100A8=3.1x10-5, pS100A9=1.4x10-4, pS100A12=5.1x10-4, two-sided student t-test) compared to other 
subjects (Fig. S2). We further explored our findings by inspecting the pathways that are most 
enriched in individual and time-varying genes, and found that genes that are implicated in immune 
system function (p=0.059) and immune diseases (p=0.041) are more present in subject-specific 
genes (Fig. 3b). This stands in contrast to pathways of core cellular functions such as genetic 170 
information processing (p=0.041) and metabolism (p=0.105), which are less present in subject-
specific genes. 
 
Discussion: Genome and transcriptome sequencing projects have unveiled millions of genetic 
variants and associated gene expression traits in humans.10 However, large-scale studies of their 175 
functional effects performed through venous blood draws require tremendous effort to undertake, 
and this is exacerbated by the cost and complexity of single-cell transcriptome sequencing. Efforts 
such as the Immune Cell Census13 are already underway to perform single-cell profiling of large 
cohorts, but reliance on venous blood draws of PBMCs will likely limit the diversity and temporal 
resolution of their sample pool. Our platform gives researchers direct, scalable access to high 180 
resolution immune system transcriptome information of human subjects, lowering the barrier of 
entry for myriad new research avenues. Examples of such studies include: 1. tracking vulnerable 
populations over time, such as monitoring clonal expansion of CD8+ T cells in Alzheimer’s disease 
progression2, 2. profiling of individuals who are under home care to track disease progression and 
therapeutic response, such as transplant patients and people under quarantine, and 3. tracking how 185 
stress, diet, and environmental conditions impact the immune system at short and long time scales, 
particularly in underrepresented populations who do not have easy access to hospitals or research 
institutions, such as people in rural or underdeveloped areas. Larger, more diverse subject pools 
coupled with time course studies of cell type gene expression in both health and disease will have 
a dramatic impact on our ability to understand the baseline and variability of immune function and 190 
disease response. 
 
Online Content 
Online web portal is available to explore data presented in the main figures for study summary, 
diurnal and subject specific genes via http://capblood-seq.caltech.edu.  195 
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Data Availability 
Gene expression matrix and relevant metadata are available on 
https://data.caltech.edu/records/1407. Genome and FASTQ files are not being released to protect 
the identity of the subjects. 200 
 
 
Code Availability  
Custom code made for diurnal and subject specific gene detection is available on 
https://github.com/thomsonlab/capblood-seq 205 
 
Methods 
 
Human Study Cohort 
This study was conducted at Caltech. Four healthy adults (2 male, 2 female) were recruited. All 210 
participants provided written informed consent. The study was approved by the Institutional 
Review Board (IRB) at Caltech and all methods were performed in compliance with relevant 
guidelines and regulations. The blood collection took place in a non-BSL room to make sure the 
subjects were not exposed to pathogens. Subject blood was collected roughly 8 hours apart over 
three consecutive days.  215 
 
CPBMC isolation 
100 µl of capillary blood was collected via push-button collection device (TAP from Seventh 
Sense Biosystems). For each blood draw, the site of collection was disinfected with an alcohol 
wipe and the TAP device was placed on the deltoid of the subject per device usage instructions. 220 
The button was pushed, and then blood was collected for 2-7 minutes until the indicator turned 
red. Blood was extracted from the TAP device by gently breaking the seal foil, and mixed with 
PBS + 2% FBS to 1 ml. The mixture was slowly added to the side of a SepMate tube (SepMate-
15 IVD, Stem Cell Technologies) containing 4.5 ml of Lymphoprep (#07811, Stem Cell 
Technologies) and centrifuged for 20 minutes at 800 RPM. Approximately 900 µl of CPBMC 225 
layer was extracted below the plasma layer. To further remove red blood cells, 100 µl of red blood 
cell lysis buffer (eBioscience 10X RBC Lysis Buffer, #00-4300-54) was added to the CPBMCs 
and incubated at RT for 15 minutes. The CPBMC pellet was washed twice with PBS and 
centrifuged at 400 rpm for 5 minutes. Cells were counted using trypan blue via an automated 
detector (Countess II Automated Cell Counter) and subjects’ cells were pooled together for 230 
subsequent single-cell RNA sequencing. 
 
Single-cell RNA sequencing 
Subject pooled single-cell suspensions were loaded onto a Chromium Single Cell Chip (10X 
Genomics) based on manufacturer’s instructions (targeted 10,000 cells per sample, 2,500 cells per 235 
person per time point). Captured mRNA was barcoded during cDNA synthesis and pooled for 
Illumina sequencing (Chromium Single Cell 3’ solution - 10X Genomics). Each time point was 
barcoded with a unique Illumina sample index, and then pooled together for sequencing in a single 
Illumina flow cell. The libraries were sequenced with an 8-base index read, 26-base read 1 
containing cell-identifying barcodes and unique molecular identifiers (UMIs), and a 91-base read 240 
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2 containing transcript sequences on a NovaSeq 6000. 
 
Single-cell Dataset Generation 
FASTQ files from Illumina were demultiplexed and aligned using Cell Ranger v3.0 
(https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines/latest/what-is-245 
cell-ranger) and the hg19 reference genome with all options set to their defaults. 
 
Sample Demultiplexing 
Subjects provided their raw data file from 23andMe (https://www.23andme.com/) sequencing for 
demultiplexing. Subjects S2 and S3 were genotyped via 23andMe’s V2 platform, and subjects S1 250 
and S4 on 23andMe’s V4 platform. 23andMe files were then converted into variant call format 
(VCF) files using 2vcf (https://github.com/arrogantrobot/23andme2vcf/) against the hg19 (human) 
reference genome, which specifies where each subject’s genome differs from the human genome 
reference. VCF files were then indexed and sorted using vcftools 
(https://github.com/vcftools/vcftools). Demuxlet (https://github.com/statgen/demuxlet) was then 255 
run on each sample using the VCF files for each subject; this generates a probability of whether 
each cell barcode belongs to each subject, given the detection of single nucleotide polymorphism 
(SNPs) in reads associated with that cell barcode. Each cell was then assigned to the subject with 
the highest probability. Cells with low confidence (ambiguous cells) and high confidence in more 
than one subject (multiplets) were discarded, using demuxlet’s default confidence thresholds. See 260 
the README at https://github.com/thomsonlab/capblood-seq for detailed instructions. 
 
Debris Removal 
The raw cell gene matrix provided by Cell Ranger contains gene counts for all barcodes present in 
the data. To remove barcodes representing empty or debris-containing droplets, a debris removal 265 
step was performed. First, a UMI count threshold was determined that yielded more than the 
expected number of cells based on original cell counts (15,000). All barcodes below this threshold 
were discarded. For the remaining barcodes, principal component analysis (PCA) was performed 
on the log-transformed cell gene matrix, and agglomerative clustering was used to cluster the cells. 
The number of clusters was automatically determined by minimizing the silhouette score among a 270 
range of numbers of clusters (6 to 15). For each cluster, a barcode dropoff trace was calculated by 
determining the number of barcodes remaining in the cluster for all thresholds in increments of 50. 
These cluster traces were then clustered into two clusters using agglomerative clustering - the two 
clusters representing “debris” with high barcode dropoff rates and “cells” with low barcode drop-
off rates. All clusters categorized as “debris” were then removed from the data. 275 
 
Gene Filtering 
Before cell typing, genes that have a maximum count less than 3 are discarded. Furthermore, after 
cell typing, any genes that are not present in at least 10% of one or more cell types are discarded.  
 280 
Data Normalization 
Gene counts were normalized by dividing the number of times a particular gene appears in a cell 
(gene cell count) by the total gene counts in that cell. Furthermore, for visualization only, the gene 
counts were multiplied by a constant factor (5000), and a constant value of 1 was added to avoid 
zeros and then log transformed. 285 
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Cell Typing 
Dimensionality reduction was applied (PCA, number of components = 50) on the log-transformed 
gene expression cell matrix. The data was then subjected to t-distributed stochastic neighbor 290 
embedding (t-SNE) to project cells to 2 dimensions for manual annotation. Visually separable 
clusters were annotated based on known immune cell type markers (Fig. S1). 
 
Diurnal Gene Detection 
To identify genes that exhibit diurnal variation in distinct cell types, we developed a statistical 295 
procedure that detects robust gene expression differences between morning (AM) and evening 
(PM) samples. Given that gene expression is different between subjects, we first normalize the 
mean gene expression within each subject for each cell type.  
𝜇′𝑔𝑖,𝑠𝑗,𝑐𝑛,𝑘 =  𝜇𝑔𝑖,𝑠𝑗,𝑐𝑛,𝑘 − (
∑ 1𝑘∈𝐴𝑀𝜇𝑔𝑖,𝑠𝑗,𝑐𝑛,𝑘
𝑁𝑠𝑗
𝑘=1
2 ∑ 1𝑘∈𝐴𝑀
𝑁𝑠𝑗
𝑘=1
+
∑ 1𝑘∈𝑃𝑀𝜇𝑔𝑖,𝑠𝑗,𝑐𝑛,𝑘
𝑁𝑠𝑗
𝑘=1
2 ∑ 1𝑘∈𝑃𝑀
𝑁𝑠𝑗
𝑘=1
)        (Eq. 1) 
 300 
We take the mean gene expression μ for each gene gi in all samples k for cell type cn and subject 
sj and renormalize it into μ’ by subtracting the equally weighted mean of AM and PM samples 
(Eq. 1). We then split the mean gene values into an AM group and a PM group and perform a 
statistical test (two-tailed student-t test) to determine whether to reject the null hypothesis that gene 
expression in AM and PM samples come from the same distribution. We then perform Benjamini-305 
Hochberg multiple comparison correction at an FDR of 0.05 on all gene and cell type p-values to 
determine where to plot the significance threshold.  For plotting the genes, we choose the Z-
statistic corresponding to the minimum p-value among cell types for that gene. To determine 
diurnality at the population level, we repeated the procedure above with all cells pooled into a 
single cell type. 310 
 
Subject and Cell Type Specific Gene Detection 
To classify genes as subject specific, we detect genes with mean gene expression levels that are 
robustly different between subjects in at least one cell type. For each cell type cn and gene gi, we 
create subject groups containing the mean gene expression values from each sample. To determine 315 
whether the gene expression means from the different subjects do not originate from the same 
distribution, we perform an ANOVA one-way test to get an F-statistic and p-value for each gene. 
We then perform Benjamini-Hochberg multiple comparison correction at an FDR of 0.05 on all 
gene and cell type p-values. For plotting the genes, we chose the F-statistic corresponding to the 
minimum p-value among cell types for that gene. 320 
For determining gene cell type specificity, we performed a similar procedure. In particular, for 
each gene gi, we create cell type groups containing the mean gene expression values for that cell 
type from each sample. We then perform a one-way ANOVA, and Benjamini-Hochberg multiple 
comparison correction at an FDR of 0.05. 
 325 
Pathway Enrichment Analysis 
Pathways from the KEGG database (python bioservices package) were used to calculate pathway 
enrichment for genes that were among the top 250 most diurnal and individual specific.  All 
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remaining genes present in the data were considered background. In order to normalize for gene 
presence across pathways, each gene was weighted by dividing the number of pathways in which 330 
that gene appears. For each KEGG pathway, the test statistic for a two-proportion z-test (python 
statsmodel v0.11.1) is used to determine pathway enrichment. From the top level pathway classes, 
we broke out “Diseases” into “Other”, “Immune Diseases”, and “Infectious Diseases” and 
separated “Immune System” from “Organismal System” to understand diurnal and subject-specific 
genes in an immune relevant context. 335 
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Supplementary Figures:
 425 
Supplementary Fig. 1 | Cell type marker gene expression in cell clusters Violin plots of log-normalized gene 
expression (y-axis, right hand side) for cell type markers (y-axis, left hand side) used to annotate cell clusters (x-axis) 
for known cell types. The colors correlate to clusters from Figure 1.d. 
 
Supplementary Fig. 2 | S100 pathway exhibits individual-specific regulation (a) Simple schematic illustrating 430 
the role of S100A8, S100A9, and S100A12 genes in immune regulation. (b) Normalized mean gene expression of 
S100A8, S100A9, and S100A12 genes for S2 showing significant downregulation in monocytes as compared to all 
cells. 
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Table S1: Genes that ranked in top 20 that had pre-existing literature tying to circadian/diurnal expression 435 
Gene DOI Reference 
DDIT4 10.7554/eLife.20214.001, 
10.1073/pnas.1800314115 
SMAP2 10.1038/s41398-019-0671-7 
RPL19 10.1128/MCB.00701-15 
RPS9 10.1073/pnas.1515308112 
PCPB1 10.1038/s41556-019-0441-z 
RPS2 10.1073/pnas.1601895113 
RPL11 10.1073/pnas.252784499 
RBM3 10.1038/srep02054 
COX5B 10.1152/physiolgenomics.00066.2007 
PDIA3 10.1002/jbmr.3046 
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